- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01978743
Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
In a cohort of HIV-infected patients who are clinically stable on the commonly use regimen of EFV/emtricitabine (FTC)/truvada (TDF) or Atripla, investigators propose to replace the EFV component with an integrase inhibitor, Raltegravir (RAL), given as the RAL and FTC/TDF to evaluate the EFV-related neural alterations. This is a multidisciplinary study which will be lead by Dr. Nina Lin, in collaboration with the research teams of Dr. Alexander Lin, Director of the Center for Clinical Spectroscopy, and Dr. Emily Stern, Director of the Functional Neuroimaging Laboratory, both members of the Brigham and Women's Department of Radiology at Harvard Medical School, as well as Dr. Jane Epstein, a researcher in Dr. Stern's research group. Dr. Epstein is a staff psychiatrist at Brigham and Women's hospital with extensive experience and expertise in research on abnormalities of affective and motivational processing in the context of neuropsychiatric disorders. Investigators will utilize the established clinical research platform in the Infectious Disease outpatient clinical practice at the Brigham and Women's Hospital, where there is currently have many ongoing HIV-related studies and a large panel of HIV-infected patients motivated to be involved in clinically relevant research. Investigators propose to use advanced neuroimaging to measure biologically changes in the brain associated with long-term EFV use with the following specific aims:
- Determine changes in neurometabolites measured by MRS in the brain associated with long-term EFV use
- Assess for alterations in neural activity correlated with affective symptoms associated with EFV vs RAL use using fMRI, and their associations with changes in neurometabolites assessed by MRS, and with changes in cognition assessed by Trail Making and Digit Substitution Tests.
- Determine changes in emotion, cognition and sleep quality after switching from EFV to RAL, and how they correlate with subject treatment preference.
This clinical study will extend our current understanding of EFV neurotoxicity by further defining the nature of these biological changes. Further elucidation of the neurobiological underpinnings of EFV-induced CNS toxicity will have clinical relevance in improving the quality of life and drug adherence of HIV-infected patients on ART, especially among older patients or those with baseline neuropsychiatric disorders, whom at baseline are more vulnerable to neurocognitive decline from long-term HIV infection.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Chronic HIV-infected individuals on suppressive regimen with EFV/FTC/TDF, for at least 6 months
- Undetectable HIV-1 RNA virus load for at least 6 months
- No co-infections with active hepatitis B and C
- Presence of at least moderate symptoms on 2 out of 3 subcores on the DASS
- No known active HIV-related and non-HIV related CNS infections
- Estimated glomerular filtration rate (EGFR) >60 ml/min
- Consent to switching to EVG/COBI/FTC/TDF
- Ages 18 - 65
Exclusion Criteria:
- History of CNS opportunistic infections or active CNS infections
- History of severe psychiatric disorder (excluding depression and anxiety)
- History of chronic neurological disorders, such as epilepsy or multiple sclerosis
- History of or current significant substance abuse or dependence and/or heavy alcohol use (>12 oz/wk)
- Any women who may be pregnant (positive urine pregnancy test or unprotected sex in 2 weeks prior to scan) or known to be pregnant
- Contraindications to undergoing fMRI, including metallic implants, claustrophobia, and medical conditions or medications that significantly affect cerebral blood flow or function.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Raltegravir
Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF).
Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
|
Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)
Zeitfenster: week 0 and week 8
|
Assess the levels of neuro-metabolites measured by MRS at week 0 before switching to the efavirenz-based therapy.
Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain creatine (Cr), gamma-aminobutyric acid (GABA) and glutathione (GLU).
|
week 0 and week 8
|
Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)
Zeitfenster: week 0 and week 8
|
Assess changes in neural activation correlated with affective disturbances associated with EFV vs. RAL using fMRI employing a paradigm that probes affective symptomatologies typical with EFV use; anxiety/dysphoria and affective dysregulation, and their association with changes in cognitive function.
Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-/Post-/ Pre-vs.
Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC).
A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect, and Age incorporated as a co-variate of no interest.
A z-score is the Mean with a SD=1 and Measure of Dispersion equal to 1.
|
week 0 and week 8
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Other Neurometabolite Changes Measured by MRS
Zeitfenster: week 0 and week 8
|
Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) to evaluate for prominent and significant changes associated with EFV use.
|
week 0 and week 8
|
Neurocognitive Changes Measured by a Panel of Indexes: WAIS-R, HAMD, DASS-21, FRSBE, STAI
Zeitfenster: week 0 and week 8
|
Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
|
week 0 and week 8
|
Fasting Lipid Profile
Zeitfenster: week 0 and week 8
|
Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.
|
week 0 and week 8
|
Sleep Quality
Zeitfenster: week 0 and week 8
|
Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI).
Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21.
The lower the score the healthier the sleep quality.
|
week 0 and week 8
|
ART Regimen Preference
Zeitfenster: week 0 and week 8
|
Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus RAL + FTC/TDF) through self-administered questionnaires.
|
week 0 and week 8
|
Markers of Immune Activation
Zeitfenster: week 0 and week 8
|
Change in markers of immune activation and inflammation associated with change to RAL (ie, sCD14, IL-6, hsCRP, D-dimer, CRP, LPS, sCD163, EndoCab)
|
week 0 and week 8
|
Change in Level of EFV and Metabolites
Zeitfenster: week 0 and week 8
|
Correlate change in level of EFV and metabolites with neurocognitive and neuroimaging changes
|
week 0 and week 8
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Nina Lin, MD, Massachusetts General Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Chemisch induzierte Störungen
- Erkrankungen des Nervensystems
- Vergiftung
- Neurotoxizitätssyndrome
- Neurokognitive Störungen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- HIV-Integrase-Inhibitoren
- Integrase-Inhibitoren
- Raltegravir Kalium
Andere Studien-ID-Nummern
- NeuroHIV002
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutierungHIV | HIV-Test | HIV-Verbindung zur Pflege | HIV-BehandlungVereinigte Staaten
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAbgeschlossenPartner-HIV-Test | HIV-Beratung für Paare | Paarkommunikation | HIV-InzidenzKamerun, Dominikanische Republik, Georgia, Indien
-
University of MinnesotaZurückgezogenHIV-Infektionen | HIV/Aids | HIV | AIDS | Aids/HIV-Problem | AIDS und InfektionenVereinigte Staaten
-
CDC FoundationGilead SciencesUnbekanntHIV-Präexpositionsprophylaxe | HIV-ChemoprophylaxeVereinigte Staaten
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement und andere MitarbeiterUnbekanntHIV | HIV-nicht infizierte Kinder | Kinder, die HIV ausgesetzt sindKamerun
-
Erasmus Medical CenterNoch keine RekrutierungHIV-Infektionen | HIV | HIV-1-Infektion | HIV-I-InfektionNiederlande
-
University of WashingtonNational Institute of Mental Health (NIMH)RekrutierungHIV-Prävention | HIV-Präexpositionsprophylaxe | ImplementierungKenia
-
University of Maryland, BaltimoreZurückgezogenHIV | Nierentransplantation | HIV-Reservoir | CCR5Vereinigte Staaten
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... und andere MitarbeiterRekrutierungHIV | HIV-Test | Verbindung zur PflegeSüdafrika
-
Hospital Clinic of BarcelonaAbgeschlossenIntegrase-Inhibitoren, HIV; HIV-PROTEASE-INHIBSpanien
Klinische Studien zur Raltegravir
-
Kirby InstituteAbgeschlossen
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico, Südafrika, Argentinien, Brasilien, Botswana
-
ViiV HealthcareAbgeschlossenInfektion, menschliches ImmunschwächevirusVereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossen
-
ViiV HealthcareGlaxoSmithKline; ShionogiAbgeschlossenHIV-Infektionen | Infektion, menschliches ImmunschwächevirusVereinigte Staaten, Frankreich, Niederlande, Spanien, Taiwan, Australien, Belgien, Russische Föderation, Kanada, Vereinigtes Königreich, Mexiko, Italien, Südafrika, Rumänien, Argentinien, Ungarn, Polen, Chile, Griechenland, Br...
-
ANRS, Emerging Infectious DiseasesAbgeschlossenHIV-1-Infektion | SCHWANGERSCHAFTFrankreich
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCAbgeschlossen
-
ViiV HealthcareGlaxoSmithKline; ShionogiAbgeschlossenInfektion, Human Immunodeficiency Virus IDeutschland, Spanien, Frankreich, Australien, Vereinigte Staaten, Kanada, Vereinigtes Königreich, Italien, Russische Föderation
-
IrsiCaixaAbgeschlossen
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-Infektionen | TuberkuloseSüdafrika